Maze Therapeutics (NASDAQ:MAZE) Rating Increased to Strong-Buy at Mizuho

Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at Mizuho to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.

A number of other equities research analysts have also recently commented on MAZE. BTIG Research restated a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Monday. Wells Fargo & Company began coverage on shares of Maze Therapeutics in a report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price objective on the stock. Raymond James Financial began coverage on shares of Maze Therapeutics in a research report on Thursday, November 13th. They set an “outperform” rating and a $48.00 price objective on the stock. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Finally, Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $54.63.

Maze Therapeutics Stock Up 2.8%

NASDAQ:MAZE opened at $51.83 on Wednesday. The company has a fifty day moving average of $44.61 and a 200-day moving average of $35.34. The firm has a market capitalization of $2.49 billion, a P/E ratio of -2.48 and a beta of 4.47. Maze Therapeutics has a twelve month low of $6.71 and a twelve month high of $52.57.

Insider Activity

In related news, insider Atul Dandekar sold 72,400 shares of the company’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.56, for a total value of $2,936,544.00. Following the sale, the insider owned 10,503 shares in the company, valued at $426,001.68. This represents a 87.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Amy Bachrodt sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.58, for a total transaction of $405,800.00. Following the completion of the transaction, the senior vice president directly owned 12,965 shares in the company, valued at approximately $526,119.70. The trade was a 43.54% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 230,000 shares of company stock worth $9,768,292 over the last three months.

Hedge Funds Weigh In On Maze Therapeutics

Several large investors have recently bought and sold shares of MAZE. Royal Bank of Canada grew its stake in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after acquiring an additional 363 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Maze Therapeutics in the fourth quarter valued at about $39,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Maze Therapeutics during the fourth quarter valued at about $43,000. California State Teachers Retirement System lifted its position in shares of Maze Therapeutics by 138.0% during the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after purchasing an additional 766 shares in the last quarter. Finally, Ameritas Investment Partners Inc. boosted its holdings in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares during the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.